Cancer Evolution

Tumour progression is driven by a process of clonal evolution. The importance of this process has been increasingly recognized over the past decade: tumour heterogeneity, the major cause of therapeutic resistance to antitumour agents, results from the genetic, epigenetic and microenvironmental selective pressure that tumour cells undergo during cancer progression.

In this collection, the cancer editorial community of the Nature journals presents the most recently published articles on cancer evolution. The topic is discussed from different complementary angles (preclinical, translational and clinical), and across a broad range of tumour types. This collection has been produced with exclusive support from EMD Serono. The collection content is editorially independent and the sole responsibility of Springer Nature.

EMD Serono is the biopharmaceutical business of Merck KGaA (Darmstadt, Germany) in the USA and Canada.

EMD Serono’s diversified oncology and immuno-oncology pipeline includes multiple projects currently in development to optimize patient outcomes in challenging cancers that have significant unmet patient needs. Our dedicated R & D translational innovation platforms are focused on using emerging science and tools to apply the principles of precision medicine to develop personalized therapies that may optimize treatment outcomes for patients.

As part of the biopharmaceutical business of Merck KGaA (Darmstadt, Germany), we are uniquely positioned to draw from the resources and experiences of our parent company in the area of oncology. In the USA, we aim to continue our strong legacy of bringing best-in-class products and solutions to patients as we move into oncology.

Read the message from the sponsor, and the message from the Prevent Cancer Foundation.